Physician profile
Keith Alan Leibowitz
NPI 1083689335
$3,254.15
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $244 · 2021: $529 · 2022: $1,035 · 2023: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.95 | 2019-2023 | |
| Janssen Biotech, INC. | $601.69 | 2019-2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $503.24 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $189.20 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.78 | 2019-2023 | Entyvio |
| Shionogi INC | $108.44 | 2019 | |
| Redhill Biopharma INC. | $86.73 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $79.86 | 2020-2023 | Linzess |
| Organon LLC | $69.43 | 2023 | Renflexis, Hadlima |
| Intercept Pharmaceuticals, INC. | $65.50 | 2019-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $64.87 | 2019-2020 | |
| Braintree Laboratories, INC. | $51.39 | 2022-2023 | Sutab |
| Celgene Corporation | $42.68 | 2023 | Zeposia |
| Ardelyx, INC. | $40.19 | 2022-2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $30.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Leibowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.